Q1 2025 Karyopharm Therapeutics Inc Earnings Call Transcript

May 12, 2025 / 08:30 PM GMT

Release Date Price: $6.15 (+2.33%)

Transcript 10-Q8-K

Key Points

Positve

Karyopharm Therapeutics Inc (KPTI) reported a successful futility analysis for their phase 3 century trial in myelofibrosis, allowing the study to continue as planned.
The company shared promising new clinical data for selenexor in combination with roxalitinib, showing potential to improve patient outcomes in myelofibrosis.
Karyopharm Therapeutics Inc (KPTI) achieved 5% demand growth year over year in Q1 2025, despite a competitive market.
The company has a strong commercial infrastructure with 80% overlap between myelofibrosis and multiple myeloma prescribers, facilitating a rapid launch if approved.
Royalty revenue increased by 57% to $1.7 million in Q1 2025, reflecting growing global demand for their products.

Negative

Karyopharm Therapeutics Inc (KPTI) experienced a $5 million increase in product return reserve due to atypical returns of expired high-dose products, impacting net product revenue.
The enrollment for the phase 3 myelofibrosis trial is slightly behind schedule, with completion now expected in June-July 2025.
Total revenue for Q1 2025 decreased to $30 million from $33.1 million in Q1 2024, partly due to increased gross-to-net provisions.
The company expects to be at the lower end of their revenue guidance range for 2025 due to atypical product returns.
Karyopharm Therapeutics Inc (KPTI) is exploring various opportunities to extend their cash runway, indicating potential financial constraints.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

KPTI.OQ - Karyopharm Therapeutics Inc
Q1 2025 Karyopharm Therapeutics Inc Earnings Call
May 12, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon. My name is Chloe, and I will be your conference operator today. At this time, I would like to welcome everyone to the KEO form of therapeutics first quarter 2025 financial results conference call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would like to turn a call over to Brandon Strong, senior Vice President investor relations and corporate communications.

Thank you. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Chloe,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.